
    
      The study is divide into two parts. In Part A the safety and tolerability of romidepsin will
      be evaluated and the effect of romidepsin treatment on HIV-1 transcription in HIV-infected
      patients virologically suppressed on cART will be determined.

      In Part B the effect of treatment with Vacc-4x + rhuGM-CSF and romidepsin treatment on the
      HIV-1 latent reservoir in HIV-infected patients virologically suppressed on cART will be
      measured.

      Six patients will be enrolled for part A and the safety and tolerability profile evaluated
      before enrolling 20 patients in B.
    
  